The winners have been announced!
Global Generics & Biosimilars Awards 2024
09 Oct 2024 - 18:00 - 23:30
GGB Awards 2024 poster announcement with date and location details. The event will be on October 9, 2024 at Hotel NH Milano Fiera.

ABOUT THE AWARDS

Join us in celebrating the 11th anniversary of the Global Generics and Biosimilars Awards, a valued recognition of outstanding accomplishments and groundbreaking innovations in the global off-patent pharmaceutical landscape. Held during CPhI Worldwide week in Milan, these prestigious Awards serve as a distinctive platform for industry leaders to convene, engage in insightful discussions about future prospects and challenges, and applaud the exceptional contributions of companies and individuals fostering positive transformations.

Celebrated across 14 distinguished categories, including Biosimilar Initiative of the Year, Leader of the Year, and API Supplier of the Year, we will honor the trailblazers shaping the industry.

Entries for the Global Generics and Biosimilars Awards are open to all at no cost. The thorough judging process will take place throughout the summer, with the announcement of finalists scheduled for September. Witness the unveiling of the winners during the Awards ceremony on Wednesday, 9 October, 2024.

Key details

  • Ceremony: Wednesday, 9 October, 2024
  • Free to attend!
  • Hotel NH Milano Fiera
THE GLOBAL GENERICS & BIOSIMILARS AWARDS CATEGORIES 2024
WHO COULD ENTER

Open to any company which has acquired another company that is active in generics and/or biosimilars, or has acquired a portfolio of generic and/or biosimilar products.


WINNER

Eurofarma Laboratórios

FINALISTS
  • Aurobindo Pharma
  • Eurofarma Laboratórios
  • Sandoz
WHO COULD ENTER

Open to any company supplying off-patent active pharmaceutical ingredients (APIs) or intermediates.


WINNER

Centrient Pharmaceuticals

FINALISTS
  • Centrient Pharmaceuticals
  • Natco Pharma
  • Surge Laboratories 
WHO COULD ENTER

Entries may relate to any biosimilar currently marketed, approved or in clinical development, sales and marketing initiatives, distribution agreements or other initiatives aimed at increasing biosimilar usage.


WINNER

Sandoz

FINALISTS
  • Biogen (Biosimilars Business Unit)
  • Boehringer Ingelheim
  • Samsung Bioepis
  • Sandoz
  • Stada
WHO COULD ENTER

Open to any generics and/or biosimilars alliance, joint venture, distribution agreement, licensing deal or similar that does not involve the acquisition of another company or a portfolio of products.


WINNER

Adalvo

FINALISTS
  • Accord Healthcare
  • Adalvo
  • Surge Laboratories
  • Unipharm
WHO COULD ENTER

This category allows industry firms and organizations to highlight outstanding campaigns used to successfully promote and highlight generics, biosimilars and value-added medicines across the world. This could include awareness campaigns, efforts to highlight key industry contributions to a wider audience, or initiatives that raise the profile of off-patent medicines for healthcare industry stakeholders.


WINNER
  • Celltrion
  • Teva Pharmaceuticals
FINALISTS
  • Accord Healthcare
  • Celltrion
  • Canadian Generic Pharmaceutical Association
  • Surge Laboratories
  • Teva Pharmaceuticals
WHO COULD ENTER

Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics or biosimilars.


WINNER

Sandoz

FINALISTS
  • Accord Healthcare
  • Aurobindo Pharma
  • Samsung Bioepis
  • Sandoz
  • Stada
WHO COULD ENTER

Open to any company that generates at least a third, or at least US$250 million, of its annual sales from generics and biosimilars. Qualification for a region is dependent on the headquarters (not tax domicile) of a company’s generics and/or biosimilars business.

  • Company of the Year — Americas | sponsored byCerba Research company logo.
    WINNER

    Dr.Reddy's – Americas

    FINALISTS
    • Amneal
    • Dr.Reddy's – Americas
    • Eurofarma Laboratórios

  • Company of the Year — Asia-Pacific
    WINNER

    Samsung Bioepis

    FINALISTS
    • Aurobindo Pharma
    • Biocon
    • Samsung Bioepis
    • Surge Laboratories - Nabiqasim Pharma Group

  • Company of the Year — EMEA
    WINNER

    Stada

    FINALISTS
    • Generis Farmacêutica, S.A.
    • Sandoz Region Europe
    • Stada
WHO COULD ENTER

Humanitarian charity International Health Partners (IHP) has partnered with Generics Bulletin to create this Award. Entries could include: company approach to CSR, implementation, engagement plans, raining & education programmes, compulsory licensing and humanitarian aid donations.


WINNER

Eurofarma Laboratórios

FINALISTS
  • Adalvo
  • Centrient Pharmaceuticals
  • Eurofarma Laboratórios
  • Hemofarm Foundation
  • Olpha (ex-Olainfarm)
WHO COULD ENTER

Awarded to recognize outstanding achievements by firms or individuals that work alongside generics and biosimilars manufacturers and suppliers. These could include logistics providers, contract-research organisations, contract-manufacturers, law firms and consultants.


WINNER

Accord Healthcare (partnership with Synthon)

FINALISTS
  • Accord Healthcare (partnership with Synthon)
  • Adalvo
  • Affygility Solutions
  • Lambda Therapeutic Research
  • Rephine
  • Surge Laboratories
WHO COULD ENTER

Open to any member of the senior management team of a firm within the generics or biosimilars industries. Judges will want to see how the entered leaders have best applied company values within the business environment – achieving measured and sustainable growth, driving improved performance, delivering shareholder value, implementing robust strategies, engaging staff, demonstrating market knowledge and true customer insight.


WINNER

Richard Saynor, CEO, Sandoz

FINALISTS
  • Paul Tredwell, Executive Vice President, Accord Healthcare EMENA
  • Anil Okay, founder and CEO, Adalvo
  • V Muralidharan (Murali), CEO, Aurobindo Pharma Europe
  • Judit Serra, Director of Innovation and Technology Development, Centrient
  • Richard Saynor, CEO, Sandoz
  • Peter Goldschmidt, CEO, Stada
WHO COULD ENTER

Awarded to identify excellence in the regulatory sphere. This could include innovative approaches to obtaining marketing authorisations, regulatory milestones for individual companies, or developments that represent a wider breakthrough for the global generics and/or biosimilars industries.


WINNER

Abyolo

FINALISTS
  • Abyolo
  • Biocon
  • Samsung Bioepis
  • Sandoz
  • Stada
WHO COULD ENTER

Entries in this category could include known molecules that are repurposed for new indications, reformulated in a way that adds value for patients, put together in innovative combinations, or which feature added-value packaging or delivery methods.


WINNER

Adalvo

FINALISTS
  • Accord Healthcare, The UK Medicines Repurposing programme
  • Accord Healthcare
  • Adalvo
  • PharmEvo
  • Surge Laboratories
HEADLINE SPONSOR

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. IQVIA creates intelligent connections to deliver powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 86,000 employees, IQVIA conducts operations in more than 100 countries. Learn more at www.iqvia.com.

Want to sponsor an award

PREVIOUS GLOBAL GENERICS & BIOSIMILARS AWARD CEREMONIES

Want to view previous Global Generics & Biosimilars Awards? Take a look back at our previous Awards and winners.
Global Generics & Biosimilars image poster
Clinical

Global Generics & Biosimilars Awards 2023

Celebrate a decade of excellence at the Global Generics and Biosimilars Awards and honour the remarkable accomplishments in the development, authorization, and distribution of global off-patent pharmaceuticals.

 

Headline sponsor

Company logo of IQVIA
Abstract blue and green spiral.
Clinical

Global Generics and Biosimilars Awards 2022

The Global Generics and Biosimilars Awards honor the remarkable accomplishments in the development, authorization, and distribution of global off-patent pharmaceuticals.

 

Headline sponsor

Company logo of IQVIA